Sensory Innovation Solutions, Inc. (SIS) is an early stage company, formed to commercialize a non-invasive, neuroscience-based stimulation platform, invented at UCLA’s Medical School. In pilot human clinical feasibility studies, the technology has shown promise in quickly resolving migraine headache pain and in reducing apnea events in pediatric and adult populations. Both of these products would serve very large markets.
FDA clearance pathways involve utilizing both Class I and Class II (510k) options, enabling the product to be commercialized quickly. SIS has an offices in Atlanta and in Riverside, California.
The company has received some initial funding from Innovation Economy Corporation (dba ieCrowd).